- NYSE:JNJ gains 0.28% on Monday to outpace the broader markets on another bearish day.
- Johnson & Johnson continues to rebound from the widespread pause of its COVID-19 vaccine.
- The pharmaceutical conglomerate is set to announce Q1 earnings on April 20th
NYSE:JNJ has had an uncharacteristically eventful week after making global headlines following some rare side effects from its COVID-19 vaccine. On Monday, Johnson & Johnson actually gained 0.28% to close the first trading day of the week at $162.69, amidst another red day for the S&P 500. Shares of Johnson & Johnson have struggled over the past year, and although the stock remains above both its 50-day and 200-day moving averages, JNJ has lagged the S&P 500 index by over 40% during the past 52-weeks.
Stay up to speed with hot stocks' news!
Johnson & Johnson found themselves at the center of a global controversy last week, as its COVID-19 vaccine was reported to have caused a rare form of blood clots in six patients. The delivery of the vaccine was halted around the world, including in Europe, South Africa, and the United States. JNJ’s goal of 100 million vaccine deliveries to the United States by the end of May could be at risk now, although many believe that the FDA and CDC will soon lift the pause in order to continue towards attaining herd immunity. In all, only about one in every million doses of Johnson & Johnson’s vaccine resulted in the rare blood clots so far.
JNJ Stock dividend
Johnson & Johnson is set to report its Q1 earnings report on Tuesday, and investors have no reason to believe it won’t be another stellar quarter from one of the largest companies in the world. JNJ currently pays a generous 2.49% dividend yield to shareholders, and with over 50 consecutive years of the company raising its dividends, it represents one of the best long-term investments available to investors.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.
Recommended content
Editors’ Picks
EUR/USD retreats toward 1.0650 after PMI-inspired rebound
EUR/USD loses traction and retreats to the 1.0650 area after rising toward 1.0700 with the immediate reaction to the upbeat PMI reports from the Eurozone and Germany. The cautious market stance helps the USD hold its ground ahead of US PMI data.
GBP/USD fluctuates near 1.2350 after UK PMIs
GBP/USD clings to small daily gains near 1.2350 in the European session on Tuesday. The data from the UK showed that the private sector continued to grow at an accelerating pace in April, helping Pound Sterling stay resilient against its rivals.
Gold flirts with $2,300 amid receding safe-haven demand
Gold (XAU/USD) remains under heavy selling pressure for the second straight day on Tuesday and languishes near its lowest level in over two weeks, around the $2,300 mark in the European session. Eyes on US PMI data.
Here’s why Ondo price hit new ATH amid bearish market outlook Premium
Ondo price shows no signs of slowing down after setting up an all-time high (ATH) at $1.05 on March 31. This development is likely to be followed by a correction and ATH but not necessarily in that order.
US S&P Global PMIs Preview: Economic expansion set to keep momentum in April
S&P Global Manufacturing PMI and Services PMI are both expected to come in at 52 in April’s flash estimate, highlighting an ongoing expansion in the private sector’s economic activity.